Showing 4481-4490 of 5805 results for "".
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant
- Tonight: DEF Webinar Series Kicks Off to Explore COVID-19 Impact on PAs, NPshttps://practicaldermatology.com/news/tonight-def-webinar-series-kicks-off-to-explore-covid-19-impact-on-pas-nps/2460331/Dermatology Education Foundation (DEF) tonight launches a new weekly video series that will focus on the impact of the COVID-19 crisis on dermatology NPs and PAs. Noting that this pandemic presents unprecedented personal and professional hardships and challenges to all practices, DEF ur
- Isdin Taps Professional Golfer Jessica Korda As New Sports Ambassadorhttps://practicaldermatology.com/news/isdin-taps-professional-golfer-jessica-korda-as-new-sports-ambassador-1/2460330/Professional golfer and LPGA star Jessica Korda is ISDIN’s new sports ambassador. As part of the campaign, Korda is sharing how she keeps her skin looking its best on and off the golf course with ISDIN products. "ISDIN formulates unique and innovative products with
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-def-leo-pharma-dermyoung-coty/2460329/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- COVID-19 Update: AAD, Others React to Potential Shortage of Malaria and Arthritis Drugshttps://practicaldermatology.com/news/covid-19-update-aad-others-react-to-potential-shortage-of-malaria-and-arthritis-drugs-1/2460320/The American Academy of Dermatology along with the Lupus Foundation of America, the American College of Rheumatology, and the Arthritis Foundation are concerned about hydroxychloroquine and chloroquine shortages and how it will impact patients with autoimmune diseases. The groups sent a
- Castle Creek Biosciences Scores $75M Investmenthttps://practicaldermatology.com/news/castle-creek-biosciences-scores-75m-investment-1/2460319/Castle Creek Biosciences, Inc. received $75 million to support the advancement of multiple gene therapy candidates for rare diseases. The company plans to use the funding to advance and expand its gene therapy pipeline, led by the Phase 3 clinical development of FCX-007
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- Pfizer's Abrocitinib Improves Atopic Dermatitis in Phase 3 Studyhttps://practicaldermatology.com/news/pfizers-abrocitinib-improves-atopic-dermatitis-in-phase-3-study/2460316/Top-line Results from a third Phase 3 trial of Pfizer's abrocitinib for moderate to severe atopic dermatitis showed improvements in skin
- CMS Updates Quality Reporting Requirements in Light of COVID-19https://practicaldermatology.com/news/cms-updates-quality-reporting-requirements/2460315/CMS is granting exceptions from reporting requirements and extensions for clinicians and providers participating in Medicare quality reporting programs with respect to upcoming measure reporting and data submission for those programs. For those programs with data submission deadl
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre